期刊文献+

不同方案治疗老年急性髓系白血病疗效分析 被引量:8

Effect of different therapeutic regimens in elderly patients with acute myeloid leukemia
下载PDF
导出
摘要 目的探讨不同治疗方案治疗老年急性髓系白血病(AML)患者的疗效和不良反应。方法 60例初治老年AML患者分别接受化疗(标准剂量、减低剂量)及姑息治疗,分析各组患者临床疗效、生存期和不良反应情况。结果 32例化疗患者有效率(RR)为62.5%,完全缓解率(CRR)为31.25%,姑息治疗组无一例患者获得完全缓解,1例获得部分缓解,RR为3.57%,两组RR差异有统计学意义(P<0.05)。标准剂量化疗RR为61.11%,CRR为33.33%;减低剂量化疗RR为64.29%,CRR为28.57%,标准剂量化疗患者与减低剂量化疗患者RR差异无统计学意义(P>0.05)。化疗组中位生存期高于姑息治疗组(P<0.05),标准剂量化疗患者与减低剂量患者中位生存期差异无统计学意义(P>0.05)。标准剂量化疗患者脏器功能障碍发生率高于减量剂量患者(P<0.05)。结论诱导化疗可改善部分老年AML患者预后,延长生存期。 Objective To explore the outcome of different therapeutic regimens in elderly patients with acute myeloid leukemia ( AML) .Methods The clinical data of 60 elderly AML patients who were treated with chemotherapy ( standard dose ,reduced dose ) and pal-liative treatment from July 2008 to July 2013 were analyzed retrospectively .The two groups were compared in therapeutic efficacy ,survival and complications.Results In the chemotherapy regime group of 32 cases,responding rate (RR) was 62.5%,and complete remission rate (CRR) was 31.25%.RR in the standard dose chemotherapy group was 61.11%,and CRR was 33.33%.In the reduced dose chemotherapy group RR was 64.29%,and CRR was 28.57%.One palliative care patients achieved PR ,and RR was 3.57%.The effective rate of chemo-therapy regime group was higher than that of palliative care group (P<0.05),but there was no difference between standard dose chmothera-pye group and reduced dose chemotherapy group (P>0.05).The median OS of chemotherapy group was longer than that of palliative treat-ment group (P<0.05).There was no difference between standard dose chemotherapy group and reduced dose chemotherapy group (P>0.05).The incidence rate of organ disfunction was higher in standard dose chemotherapy group than in reduced dose group (P<0.05).Con-clusions Induction chemotherapy can improve the survival time of partial elderly patients with AML and improve the prognosis .
出处 《安徽医学》 2014年第9期1213-1215,共3页 Anhui Medical Journal
关键词 老年 急性髓系白血病 诱导化疗 姑息治疗 Elderly Acute myeloid leukemia Induction chemotherapy Palliative care
  • 相关文献

参考文献2

共引文献182

同被引文献55

  • 1冀晓红.糖胺聚糖方案治疗老年急性髓系白血病的疗效及预后影响因素[J].中国老年学杂志,2015,35(2):374-375. 被引量:6
  • 2Rowe JM.Optimal induction and post-remission therapy for AML in first remission[J].Hematology Am Soc Hematol Educ Program,2009,2009:396-405.
  • 3Gyurkocza B,Storb R,Storer BE,et al.Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia[J].J Clin Oncol,2010,28(17):2859-2867.
  • 4Luger SM.Treating the elderly patient with acute myelogenous leukemia[J].Hematology Am Soc Hematol Educ Program,2010,20(10):62-69.
  • 5Shi P,Zha J,Guo X,et al.Idarubicin is superior to daunorubicin in remission induction of denovo acute myeloid leukemia patients with high MDR1 expression[J].Pharmacogenomics,2013,14(1):17-23.
  • 6Faderl S,Ravandi F,Huang X,et al.Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients[J].Cancer,2012,118(18):4471-4477.
  • 7So CC,Wan TS,Chow JL,et al.A single center cytogenetic study of 629 Chinese patients with de novo acute myeloid leukemia-evidence of major ethnic differences and a high prevalence of acute promyelocytic leukemia in Chinese patients[J].Cancer Genet,2011,204(8):430-438.
  • 8Ravandi F,Burnett AK,Agura ED,et al.Progress in the treatment of acute myeloid leukemia[J].Cancer,2007,110(9):1900.
  • 9Juliusson G,Antunovic P,Derolf A,et al.Age and acute myeloid leukemia:real world data on decision to treat and out comes from the Swedish Acute Leukemia Registry[J].Blood,2009,113(18):4179-4187.
  • 10王建祥.规范我国成人急性髓系白血病诱导治疗完全缓解患者的分层治疗[J].中华血液学杂志,2009,30(1):1-2. 被引量:4

引证文献8

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部